- Home
- ALMU vs LRMR Comparison
ALMU vs LRMR Comparison
Compare ALMU & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALMU
- LRMR
- Stock Information
- Founded
- ALMU 2019
- LRMR N/A
- Country
- ALMU United States
- LRMR United States
- Employees
- ALMU N/A
- LRMR N/A
- Industry
- ALMU Semiconductors
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- ALMU Technology
- LRMR Health Care
- Exchange
- ALMU Nasdaq
- LRMR Nasdaq
- Market Cap
- ALMU 206.9M
- LRMR 183.8M
- IPO Year
- ALMU N/A
- LRMR N/A
- Fundamental
- Price
- ALMU $14.26
- LRMR $2.25
- Analyst Decision
- ALMU
- LRMR Strong Buy
- Analyst Count
- ALMU 0
- LRMR 8
- Target Price
- ALMU N/A
- LRMR $19.63
- AVG Volume (30 Days)
- ALMU 194.7K
- LRMR 1.3M
- Earning Date
- ALMU 05-07-2025
- LRMR 04-30-2025
- Dividend Yield
- ALMU N/A
- LRMR N/A
- EPS Growth
- ALMU N/A
- LRMR N/A
- EPS
- ALMU N/A
- LRMR N/A
- Revenue
- ALMU $3,627,488.00
- LRMR N/A
- Revenue This Year
- ALMU N/A
- LRMR N/A
- Revenue Next Year
- ALMU N/A
- LRMR N/A
- P/E Ratio
- ALMU N/A
- LRMR N/A
- Revenue Growth
- ALMU 335.67
- LRMR N/A
- 52 Week Low
- ALMU $2.50
- LRMR $1.61
- 52 Week High
- ALMU $18.00
- LRMR $11.20
- Technical
- Relative Strength Index (RSI)
- ALMU N/A
- LRMR 54.28
- Support Level
- ALMU N/A
- LRMR $1.80
- Resistance Level
- ALMU N/A
- LRMR $2.33
- Average True Range (ATR)
- ALMU 0.00
- LRMR 0.19
- MACD
- ALMU 0.00
- LRMR 0.03
- Stochastic Oscillator
- ALMU 0.00
- LRMR 86.67
About ALMU Aeluma Inc. Common Stock
Aeluma Inc is a semiconductor company specializing in sensors and communications. It is developing sensor technology for mobile devices and vehicles. The company develops novel optoelectronic devices for sensing and communications applications. The company manufactures devices using high-performance compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass-market microelectronics. The applications include mobile, automotive, AI, defense & aerospace, communication, AR/VR and quantum computing.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.